Your diversified EIS portfolio
Fund Twenty8 is no longer open to new investments. Please visit our Access EIS Fund page if you wish to make an investment.
Fund Twenty8 follows the decisions of sophisticated private and professional investors to automatically build you a diversified portfolio of no fewer than 28 EIS-qualifying startups.
The fund’s strategy is based on extensive research conducted by NESTA and Intelligent Partnership, which asked the question: how many startup investments should I have?
The magic number appears to be: no fewer than 28. With this many startups in your portfolio, the study suggests a 95% chance of at least one giving you a return of 10X or more. With this in mind, the fund is targeting a return of over 20% IRR, including up to 30% EIS tax relief.
Independent review
Fund Twenty8 received an independent review from MJ Hudson Allenbridge, a leading independent investment advisory and investment research group, providing independent advice, due diligence and analytical solutions to help institutional investors make better investment decisions.
This independent review has not been commissioned by SyndicateRoom. It has not been issued or approved by SyndicateRoom. It is not a recommendation to invest and does not constitute advice.
Our portfolio
While traditional EIS funds normally invest in just a few companies, covering limited sectors, Fund Twenty8 backs a minimum of 28 per fund, per year, offering truly sector-agnostic diversification.
Having just finished deploying its second fund, Fund Twenty8 has:
- 426 investors
- Invested a total of £8.54m
- Diversified over 64 investments
- Across 13 sectors
Review
I’ve been investing in individual companies and have built up a sizeable portfolio, but I’d not invested in EIS funds until I discovered Fund Twenty8.
The focus on diversification makes a lot of sense to me and I think that using the personal investment decisions of numerous savvy investors to deploy capital is a very clever model.
Suraj Rajan
Fund Twenty8 investor
Investment strategy
Invest alongside lead investors
Mitigate risk by building a sector-agnostic and diversified portfolio across no fewer than 28 Qualifying Investments
Target development capital in companies that are:
- Ideally in revenue, which can provide shorter times to exit
- Usually pre-profit
- Able to demonstrate strong and established management teams with proven business credentials
- Aiming to generate an IRR of 20% or more (inc EIS)
- EIS eligible at the time of investment and the Manager will seek to retain EIS eligibility as appropriate
By following the investment decisions of some of the savviest private investors, Fund Twenty8 automatically builds you a diversified portfolio of no fewer than 28 EIS-qualifying startups. The portfolio of every iteration of Fund Twenty8 will be added to this page as they finish deploying.
Fund Twenty8-2017 portfolio
Fund Twenty8's 2017 portfolio consists of 32 investments spanning ten sectors. As our portfolio grows and raises further capital, we look forward to seeing its companies succeed.
FUND TWENTY8-2017 PORTFOLIO COMPANIES
Bockatech
ENGINEERING
Interpac
ENGINEERING
Greenspur Renewables
ENVIRONMENT
Naked Energy
ENVIRONMENT
Pass the Keys
MARKETPLACES
Pekama
MARKETPLACES
LuckyTrip
MARKETPLACES
Ambicare
LIFE SCIENCES
Arcis Biotechnology
LIFE SCIENCES
Cipher Surgical
LIFE SCIENCES
EnteroBiotix
LIFE SCIENCES
Gemetix Healthcare
LIFE SCIENCES
Molecular Warehouse
LIFE SCIENCES
MGB Biopharma
LIFE SCIENCES
Metrion Biosciences
LIFE SCIENCES
Fund Twenty8-2016 portfolio
The first Fund Twenty8 closed in 2017 and finished deploying in 2018. By September, the portfolio was valued at 108% (paper value). Its final portfolio is a testament to the fund's mission: to deliver investors a large and diversified portfolio of at least 28 investments.
- 233 investors took part
- Invested a total of £4.55m
- Diversified over 32 investments
- Across 10 sectors
FUND TWENTY8-2016 PORTFOLIO COMPANIES
Dymag
ENGINEERING
Alert Technology
ENVIRONMENT
USIO
ENVIRONMENT
Pekama
MARKETPLACES
Starstock
MARKETPLACES
Celame
MARKETPLACES
Biotechspert
MARKETPLACES
Make it Social
MARKETPLACES
e-Patient Network
HEALTHCARE
Dem DX
HEALTHCARE
Emoquo
HEALTHCARE
SupaPass
MEDIA
Peptinnovate
PHARMA
Re-Vana Therapeutics
PHARMA
Digital Therapeutics
PHARMA
